Introduction: Rationale for using drotrecogin alfa (activated) in patients with severe sepsis

American Journal of Surgery

Volumn 184, Issue 6 SUPPL. 1, 2002, Pages S5-S10

  Dhainaut, Jean François ^a  

^a Cochin Port Royal Univ Hospital ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN;

ARTICLE; BLEEDING; BLOOD CLOTTING; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG MECHANISM; EUROPE; HEALTH CARE COST; HOSPITAL INFECTION; HUMAN; INCIDENCE; INTENSIVE CARE; MEDICAL LITERATURE; MORTALITY; MULTIPLE ORGAN FAILURE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT SELECTION; PRIORITY JOURNAL; SEPSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 0036944375     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(02)01137-6     Document Type: Article

References (57)

1. Angus D.C., Linde-Zwirble W.T., Lidicker J., et al. Epidemiology of severe sepsis in the United States analysis of incidence, outcome, and associated costs of care . Crit Care Med. 29:2001;1303-1310.
2. Davies A, Green C, Hutton J, Chinn C. Severe sepsis: A European estimate of the burden of disease in ICU. Intensive Care Med 2001;27(suppl):S284. Abstract 581.
3. Linde-Zwirble W.T., Angus D.C., Carcillo J., et al. Age-specific incidence and outcome of sepsis in the US. [abstract] Crit Care Med. 27:1999;A33.
4. Natanson C., Esposito C.J., Banks S.M. The sirens' songs of confirmatory sepsis trials selection bias and sampling error . Crit Care Med. 26:1998;1927-1931.
5. Murphy S.L. Deaths final data for 1998 . Natl Vital Stat Rep. 48:2000;1-105.
6. Aderem A., Ulevitch R.J. Toll-like receptors in the induction of the innate immune response. Nature. 406:2000;782-787.
7. McGilvray I.D., Rotstein O.D. Role of the coagulation system in the local and systemic inflammatory response. World J Surg. 22:1998;179-186.
8. Vervloet M.G., Thijs L.G., Hack C.E. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Haemost. 24:1998;33-44.
9. Levi M., ten Cate H. Disseminated intravascular coagulation. N Engl J Med. 341:1999;586-592.
10. van Gorp E.C., Suharti C., ten Cate H., et al. Review infectious diseases and coagulation disorders . J Infect Dis. 180:1999;176-186.
11. Parrillo J.E. Pathogenetic mechanisms of septic shock. N Engl J Med. 328:1993;1471-1477.
12. van der Poll T., Buller H.R., ten Cate H., et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med. 322:1990;1622-1627.
13. van Deventer S.J., Buller H.R., ten Cate J.W., et al. Experimental endotoxin in humans analysis of cytokine release and coagulation, fibrinolytic, and complement pathways . Blood. 76:1990;2520-2526.
14. Carvalho A.C., Freeman N.J. How coagulation defects alter outcome in sepsis survival may depend on reversing procoagulant conditions . J Crit Illness. 9:1994;51-75.
15. Hinshaw L.B. Sepsis/septic shock participation of the microcirculation: an abbreviated review . Crit Care Med. 24:1996;1072-1078.
16. Asaka S., Shibayama Y., Nakata K. Pathogenesis of focal and random hepatocellular necrosis in endotoxemia microscopic observation in vivo . Liver. 16:1996;183-187.
17. Esmon C.T. Introduction are natural anticoagulants candidates for modulating the inflammatory response to endotoxin? Blood. 95:2000;1113-1116.
18. Bone R.C., Grodzin C.J., Balk R.A. Sepsis a new hypothesis for pathogenesis of the disease process . Chest. 112:1997;235-243.
19. Dinarello C.A. Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest. 112:(6 suppl):1997;321S-329S.
20. Antonelli M. Sepsis and septic shock proinflammatory or anti-inflammatory state? J Chemother. 11:1999;536-540.
21. van der Poll T., van Deventer S.J. Cytokines and anticytokines in the pathogenesis of sepsis. Infect Dis Clin North Am. 13:1999;413-426.
22. Calandra T., Heumann D. Inhibitory cytokines. Marshall J.C., Cohen J. Immune Response in the Critically Ill. 2000;67-83 Springer, New York.
23. Cavaillon J.M., Adib-Conquy M. The pro-inflammatory cytokine cascade. Marshall J.C., Cohen J. Immune Response in the Critically Ill. 2000;37-66 Springer, New York.
24. Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol. 20:2000;2511-2518.
25. Suffredini A.F., Harpel P.C., Parrillo J.E. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med. 320:1989;1165-1172.
26. Dhainaut J.F., Marin N., Cariou A. Perspectives in anti-inflammatory therapies in sepsis. Eichacker P.Q., Pugin J. Evolving Concepts in Sepsis and Septic Shock. 2001;145-161 Kluwer Academic Publishers, Boston.
27. Esmon C.T. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem. 264:1989;4743-4746.
28. Esmon C.T., Xu J., Gu J.M., et al. Endothelial protein C receptor. Thromb Haemost. 82:1999;251-258.
29. Fourrier F., Chopin C., Goudemand J., et al. Septic shock, multiple organ failure and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest. 101:1992;816-823.
30. Lorente J.A., García-Frade L.J., Landín L., et al. Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest. 103:1993;1536-1542.
31. Powars D., Larsen R., Johnson J., et al. Epidemic meningococcemia and purpura fulminans with induced protein C deficiency. Clin Infect Dis. 17:1993;254-261.
32. Boldt J., Papsdorf M., Rothe A., et al. Changes of the hemostatic network in critically ill patients is there a difference between sepsis, trauma, and neurosurgery patients? Crit Care Med. 28:2000;445-450.
33. Fisher C.J., Yan S.B. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med. 28:(9 suppl):2000;S49-S56.
34. Mesters R.M., Helterbrand J., Utterback B.G., et al. Prognostic value of protein C levels in neutropenic patients at high risk of severe septic complications. Crit Care Med. 28:2000;2209-2216.
35. Yan S.B., Helterbrand J.D., Hartman D.L., et al. Low levels of protein C are associated with poor outcome in severe sepsis. Chest. 120:2001;915-922.
36. Dhainaut J.F., Marin N., Mignon A., Vinsonneau C. Hepatic response to sepsis interaction between coagulation and inflammatory processes . Crit Care Med. 29:(suppl):2001;S42-S47.
37. Moore K.L., Andreoli S.P., Esmon N.L., et al. Endotoxin enhances tissue factor and supresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest. 79:1987;124-130.
38. Moore K.L., Esmon C.T., Esmon N.L. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood. 73:1989;159-165.
39. Lentz S.R., Tsiang M., Sadler J.E. Regulation of thrombomodulin by tumor necrosis factor-alpha comparison of transcriptional and posttranslational mechanisms . Blood. 77:1991;542-550.
40. MacGregor I.R., Perrie M., Donnelly S.C., Haslett C. Modulation of human endothelial thrombomodulin by neutrophils and their release products. Am J Respir Crit Care Med. 155:1997;47-52.
41. Gu J.M., Katsuura Y., Ferrell G.L., et al. Endotoxin and thrombin elevate rodent endothelial cell protein C receptor mRNA levels and increase receptor shedding in vivo. Blood. 95:2000;1687-1693.
42. Kurosawa S., Stearns-Kurosawa D.J., Carson C.W., et al. Plasma levels of endothelial cell protein C receptor are elevated in patients with sepsis and systemic lupus erythematosus lack of correlation with thrombomodulin suggests involvement of different pathological processes . Blood. 91:1998;725-727.
43. Faust S.N., Levin M., Harrisson O.B., et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med. 345:2001;408-416.
44. Taylor F.B. Jr, Wada H., Kinasewitz G. Description of compensated and uncompensated disseminated intravascular coagulation (DIC) responses (non-overt and overt DIC) in baboon models of intravenous and intraperitoneal Escherichia coli sepsis and in the human model of endotoxemia toward a better definition of DIC . Crit Care Med. 28:(9 suppl):2000;S12-S19.
45. Jackson CV, Shetler TJ, Bailey BD. Recombinant human activated protein C (LY203638)-induced reperfusion in a canine model of occlusive coronary artery thrombosis. Circulation 1998;98(suppl 1):I454. Abstract 2390.
46. Bajzar L., Nesheim M., Tracy P.B. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood. 88:1996;2093-2100.
47. Grinnell B.W., Yan S.B. Novel antithrombotics based on modulation of the protein C pathway. Coronary Artery Dis. 9:1998;89-97.
48. Esmon C.T. The normal role of activated protein C in maintaining homeostasis and its relevance to critical illness. Crit Care. 5:2001;S7-S12.
49. Esmon C.T. The endothelial cell protein C receptor. Thromb Haemost. 83:2000;639-643.
50. Esmon C.T. The anticoagulant and anti-inflammatory roles of the protein C anticoagulant pathway. J Autoimmun. 15:2000;113-116.
51. White B., Schmidt M., Murphy C., et al. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor κB (NF-κB) and tumor necrosis factor α (TNF-α) production in the THP-1 monocyte cell line. Br J Haematol. 110:2000;130-134.
52. Taylor F.B. Jr, Chang A., Esmon C.T., et al. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest. 79:1987;918-925.
53. Taylor F.B. Jr, Stearns-Kurosawa D.J., Kurosawa S., et al. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood. 95:2000;1680-1686.
54. Taylor F.B. Jr, Peer G.T., Lockhart M.S., et al. Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood. 97:2001;1685-1688.
55. Roback M.G., Stack A.M., Thompson C. Activated protein C concentrate for the treatment of meningococcal endotoxin shock in rabbits. Shock. 9:1998;138-142.
56. Fourrier F., Jourdin M., Tournoys A. Effects of combined antithrombin III and protein C supplementation in porcine acute endotoxin shock. Shock. 10:1998;364-370.
57. Bernard G.R., Vincent J.L., Laterre P.F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 344:2001;699-709.